Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid beta (Aβ) peptide is a short polypeptide, typically 36–43 amino acids in length, derived from the amyloid precursor protein (APP) through sequential cleavage by β- and γ-secretases. The most common forms are Aβ40 and Aβ42, containing 40 and 42 residues respectively. These peptides are central to the pathology of Alzheimer’s disease due to their propensity to aggregate into oligomers and fibrils that form amyloid plaques in the brain. In its monomeric form, Aβ is mostly unstructured, but it can transition to β-sheet structures upon aggregation. While the physiological function of monomeric Aβ remains unclear, its aggregated forms are highly neurotoxic and play a key role in Alzheimer's disease pathology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amyloid beta peptide (monomer) (Aβ).